Sana Biotechnology

biotechnology company

SANA Nasdaq SEC CIK 1770121
Follow Sana Biotechnology Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income $20.4M +148.4% vs same quarter last year
EPS, diluted $0.07 +143.8% vs same quarter last year
Operating cash flow −$38.8M −31.7% vs same quarter last year
Operating income $18.5M +142.5% vs same quarter last year
Net income by quarter
−$49.1M
−$49.4M
−$93.8M
−$42.2M
−$58.8M
−$47.2M
−$63.6M
$20.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
−$400M−$300M−$200M−$100M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$244.2M
FY24−$266.8M
FY23−$283.3M
FY22−$269.5M
FY21−$355.9M
FY20−$285.3M
FY19−$130.8M
FY18-
Free cash flowOperating cash flow minus capital expenditure
−$400M−$300M−$200M−$100M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$144.8M
FY24−$256.6M
FY23−$273.6M
FY22−$310.9M
FY21−$280.9M
FY20−$161.9M
FY19−$111.6M
FY18-